You are here: Home / Breast / Evista for Breast Cancer in postmenopausal women

Evista for Breast Cancer in postmenopausal women

September 19, 2007 By Doctor Leave a Comment

 

Evista (Raloxifene) was approved for Breast cancer treatment by Food and Drug administration for some post-menopausal women. After Tamoxifen, Evista is the second drug approved for breast cancer treatment. Evista should not be prescribed for all women because of serious side effects.

 

 

Evista is advised for treatment in two groups of women to lower the risk of invasive breast cancer.

 

1. Postmenopausal women with osteoporosis.

 

2. Postmenopausal women at high risk for invasive breast cancer.

 

 

 
 
 
Breast Cancer is the second most common cause of cancer deaths in women. It accounts for 26% of all cancers among US women. According to American Cancer Society, 0.18 Million American women are diagnosed with invasive breast cancer each year.
 
 
 
Evista is a SERM (Selective Estrogen Receptor Modulator) manufactured by Eli Lilly. It is used to prevent osteoporosis in postmenopausal women.
 
 
 
 
Side effects of Evista:
 
 
 
1. Blood clots in the legs, eyes and lungs. Women who have previous history of clots should not take Evista.

 
2. Hot flashes, leg cramps, swelling of the legs and feet, flu-like symptoms, joint pain and sweating.

 
3. Evista should not be taken by premenopausal women and pregnant women because of serious harm to the foetus.

 
4. Evista should not be taken along with estrogens or Cholestyramine.

 

 

Tamoxifen is the best drug for premenopausal women who have a breast cancer risk while Raloxifene is preferred for postmenopausal women. Evista does not treat existing breast cancer.
 

Oncologist should weigh potential benefits and risks before prescribing Evista to postmenopausal women who are at high risk for invasive breast cancer.

 

 

 

Related posts:

  1. Exercise and yoga help breast cancer women in early stage   According to latest research studies, Yoga and Aerobic exercise help to improve quality of life in early-stage breast cancer patients. Results of the research study were published in the...
  2. FDA approved Wyeth drug Torisel for renal cell carcinoma   Food and Drug Administration (FDA) approved Wyeth drug, Temsirolimus (Torisel), for the treatment of advanced kidney cancer, renal cell carcinoma. According to company research, it has shown better results...
Filed Under: Breast Tagged With: , , ,

Speak Your Mind

*

Copy Protected by Chetan's WP-CopyProtect.